Sign inJoin waitlistJoin the waitlist

Kavitha Ramaswamy

Assistant Attending Pediatrician · New York Presbyterian Hospital

Credentials: · ·

History

New York Presbyterian Hospital
Present

Pediatric Hematology/Oncology
New York Presbyterian Hospital
2014–2017
Memorial Sloan Kettering Cancer Center
2013–2014
Pediatrics
New York Presbyterian Hospital
2010–2013
Rutgers, Robert Wood Johnson Medical School
2006–2010

Research

Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2α
Cell Metabolism · 2013 · 167 citations
Alterations in cortisol secretory dynamics in adolescent girls with anorexia nervosa and effects on bone metabolism
The Journal of Clinical Endocrinology & Metabolism · 2004 · 153 citations
Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin…
The Journal of Clinical Endocrinology & Metabolism · 2004 · 98 citations

CF
Christopher Forlenza
7 papers
NS
Neerav Shukla
7 papers
PS
Peter Steinherz
5 papers
TT
Tanya Trippett
4 papers
AK
Anne Klibanski
3 papers
DH
David Herzog
3 papers
Karen Miller
3 papers
Madhusmita Misra
3 papers
MS
Maria Sulis
3 papers
Adit Tal
2 papers
Alex Kentsis
2 papers
AC
Alexander Chou
2 papers

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2020–2028
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Site PI · Recruiting · Phase 3
Children's Oncology Group
2019–2032